BioSpace News Archive

Zimmer Biomet Holdings, Inc., a global medical technology leader, hosted its 2024 Investor Day and provided an in-depth review of the Company’s strategic priorities and long-range plan for growth and value creation.

Aeterna Zentaris Inc. announced that it is making an application for an order pursuant to section 133 of the Canada Business Corporations Act extending the time for the Company to call and hold its annual meeting of its shareholders to a date that is not later than July 31, 2024.

Full-Life Technologies, a fully integrated global radiotherapeutics company, announced it has received clearance of its Investigational New Drug Application from the U.S. Food and Drug Administration for clinical trials of 225Ac-FL-020, its PSMA-targeted radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer.

Anaveon, a clinical stage, immuno-oncology company, announced that its Investigational New Drug application to conduct a Phase I/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA.

BerGenBio ASA, a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced financial results for the quarter ended March 31, 2024, and provided a business update.

NanoViricides, Inc., a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its development of a first-in-class, broad-spectrum antiviral agent that could revolutionize treatment of viral infections including RSV, COVID, Influenzas and other viruses.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, announced that the Company will participate in fireside chats at the following upcoming investor events.

Omega Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, announced the appointment of Kaan Certel, Ph.D., as Chief Business Officer.

IGM Biosciences, Inc. announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York.

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the Jefferies Global Healthcare Conference, at 5:30 p.m. ET on Wednesday, June 5, 2024, in New York City.